It is noteworthy that the anti‐cancer activity of MDM2‐inhibitor is mainly dependent on a functional p53, and we further confined the potential beneficial group from MDM2 inhibition to NSCLC patients carrying wild‐type TP53 and RTKs to maximize the efficacy. The gene discussed is MDM2; the disease is cancer.